


## Data Sheet

[WWW.UREIKO-CHEM.COM](http://WWW.UREIKO-CHEM.COM)

Global Supplier of Chemical Probes, Inhibitors & Agonists

**Product Name** :FX-909  
**Cat.No.** :URK-V2454  
**CAS No.** :2924573-90-8  
**Molecular Formula** :C<sub>17</sub>H<sub>10</sub>F<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S  
**Molecular Weight** :360.33  
**Target** :  
**Solubility** :



### Biological Activity

FX-909 is a novel, potent, selective inhibitor of kinase 7 (CDK7).

CDK7 is a key player in the regulation of transcription, the process by which genetic information is converted into proteins. By inhibiting CDK7, FX-909 disrupts the progression of the cell cycle, which is often dysregulated in cancer cells. This leads to a decrease in the proliferation of cancer cells and ultimately tumor growth.

Preclinical studies have shown that FX-909 has potent antitumor activity in various cancer cell lines, including breast, lung, and prostate cancers. In addition, it has demonstrated favorable pharmacokinetic properties and good tolerability in animal models.

### References

1. Chipumuro E, Marco E, Christensen CL, et al. CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. *Cell*. 2014;159(5):1126-39.
2. Cao Q, Lu X, Feng Y, Li K, Wang L, Lv Y. CDK7 inhibition is a promising therapeutic approach in solid tumors. *BMC Cancer*. 2019;19(1):758.
3. Kwiatkowski N, Zhang T, Rahl PB, et al. Targeting transcription regulation in cancer with a covalent CDK7 inhibitor. *Nature*. 2014;511(7511):616-20.

*Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!*

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

[JACK@UREIKO-CHEM.COM](mailto:JACK@UREIKO-CHEM.COM)